Stockscreener 앱 받기
150.82
1.30%
1.94
시간 외 거래:
150.82
전일 마감가:
$148.88
열려 있는:
$147.28
하루 거래량:
656.19K
Relative Volume:
0.45
시가총액:
$11.50B
수익:
$8.19B
순이익/손실:
$758.19M
주가수익비율:
16.43
EPS:
9.18
순현금흐름:
$1.06B
1주 성능:
+3.37%
1개월 성능:
+17.01%
6개월 성능:
-29.07%
1년 성능:
-52.62%
1일 변동 폭
$146.35
$151.39
1주일 범위
$142.89
$155.25
52주 변동 폭
$125.10
$347.72
Icon Plc Stock (ICLR) Company Profile
ICLR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
150.82 | 11.50B | 8.19B | 758.19M | 1.06B | 9.18 |
|
TMO
Thermo Fisher Scientific Inc
|
427.76 | 156.49B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
202.50 | 145.01B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
542.71 | 42.30B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
120.66 | 34.24B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
164.65 | 27.64B | 15.50B | 1.33B | 2.16B | 7.34 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-04-14 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-04-10 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-03-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-01-07 | 개시 | RBC Capital Mkts | Outperform |
| 2024-10-24 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-10-14 | 개시 | Redburn Atlantic | Neutral |
| 2024-09-18 | 개시 | Leerink Partners | Outperform |
| 2024-06-06 | 개시 | Goldman | Buy |
| 2023-12-15 | 개시 | Truist | Buy |
| 2023-09-13 | 개시 | TD Cowen | Outperform |
| 2023-01-17 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-01-13 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2022-11-09 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-09-07 | 개시 | UBS | Buy |
| 2022-08-25 | 개시 | Credit Suisse | Neutral |
| 2022-05-24 | 개시 | Guggenheim | Buy |
| 2022-04-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-04-12 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2021-09-27 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-08-05 | 재개 | Credit Suisse | Outperform |
| 2021-07-23 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-07-14 | 개시 | Citigroup | Neutral |
| 2021-04-13 | 재개 | BofA Securities | Neutral |
| 2021-04-01 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2021-03-08 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2021-03-03 | 개시 | Barclays | Equal Weight |
| 2021-03-01 | 업그레이드 | UBS | Neutral → Buy |
| 2021-02-26 | 업그레이드 | Truist | Hold → Buy |
| 2020-07-24 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-04-20 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-03-02 | 개시 | Deutsche Bank | Hold |
| 2020-01-27 | 다운그레이드 | SunTrust | Buy → Hold |
| 2020-01-08 | 개시 | Wells Fargo | Equal Weight |
| 2020-01-07 | 개시 | Citigroup | Neutral |
| 2019-09-23 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-07-26 | 업그레이드 | UBS | Sell → Neutral |
| 2019-01-25 | 업그레이드 | Mizuho | Neutral → Buy |
| 2018-10-26 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-10-09 | 개시 | UBS | Sell |
| 2018-04-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2018-02-15 | 재확인 | Mizuho | Neutral |
| 2018-01-19 | 개시 | Evercore ISI | Outperform |
| 2017-10-27 | 재확인 | Barclays | Equal Weight |
| 2017-09-11 | 개시 | BofA/Merrill | Buy |
| 2017-07-31 | 업그레이드 | SunTrust | Hold → Buy |
| 2017-07-27 | 재확인 | Mizuho | Neutral |
| 2017-06-29 | 업그레이드 | Jefferies | Hold → Buy |
모두보기
Icon Plc 주식(ICLR)의 최신 뉴스
ICON plc Reports Strong Interim Financial Results for Early 2025 - TipRanks
Medical Device Regulatory Affairs Market Top PlayersICON, - openPR.com
ICON plc Announces 2025 AGM and Key Resolutions - TipRanks
Icon PLC (ICLR) Shares Up 3.47% on Jun 6 - GuruFocus
Regulatory Affairs Outsourcing Market Analysis Report 2025: Globalization of Biopharmaceutical and Medical Device Companies Bolster Growth - GlobeNewswire Inc.
ICON Public Limited (NASDAQ:ICLR) Short Interest Up 25.4% in May - Defense World
Icon PLC (ICLR) Stock Price Up 4.49% on Jun 4 - GuruFocus
ICON Becomes the First Large Clinical Research Organization to Fully Integrate Medidata Clinical Data Studio, Streamlining Data Management and Review - mx.advfn.com
Here's Why You Should Retain ICLR Stock in Your Portfolio Now - TradingView
Icon PLC (ICLR) Down 9.7% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
ICON plc to Present at the William Blair 45th Annual Growth Stoc - GuruFocus
ICON plc to Present at Annual Growth Stock Conference By Investing.com - Investing.com South Africa
ICLR December 2026 Options Begin Trading - Nasdaq
ICON plc to Present at the William Blair 45th Annual Growth Stock Conference - BioSpace
ICON plc to Present at Annual Growth Stock Conference - Investing.com
ICON plc to Present at William Blair Growth Stock Conference - TipRanks
ICON’s SWOT analysis: cro stock faces headwinds amid potential rebound - Investing.com
ICON Life Science Internship For BSc & MSc – Applications Closing Soon! Hurry! - BioTecNika
Redburn Atlantic Adjusts Icon (ICLR) Price Target Amid Market Uncertainty | ICLR Stock News - GuruFocus
ICON Plc stock hits 52-week low at $127.51 amid market challenges By Investing.com - Investing.com South Africa
ICON Plc stock hits 52-week low at $127.51 amid market challenges - Investing.com Nigeria
ICON releases its ICON Cares 2024 Report | ICLR Stock News - GuruFocus
ICON releases its ICON Cares 2024 Report - Silicon Canals
ICON Releases ICON Cares 2024 Report Highlighting ESG Achievements - TipRanks
Icon (ICLR) Maintains Outperform Rating Amid Price Target Adjustment | ICLR Stock News - GuruFocus
Icon (ICLR) Price Target Reduced by Mizuho to $173 | ICLR Stock News - GuruFocus
Daily Progress: Icon Plc (ICLR) Drop -5.54, Closing at 135.10 - DWinneX
Global ICON survey shows need for more efficient obesity clinical trial design to realise full potential of next-gen multi-indication therapies | ICLR Stock News - GuruFocus
Global ICON survey shows need for more efficient obesity clinical trial design to realise full potential of next-gen multi-indication therapies - Business Wire
Icon (ICLR) Stock Target Reduced Amid Market Challenges | ICLR S - GuruFocus
Icon (ICLR) Stock Target Reduced Amid Market Challenges | ICLR Stock News - GuruFocus
ICON plc (ICLR) Consensus: A 29% Potential Upside Sparks Investor Interest - DirectorsTalk Interviews
Icon Plc Earnings Call: Navigating Challenges and Opportunities - TipRanks
Icon (ICLR) Sees Price Target Adjustment by Barclays | ICLR Stock News - GuruFocus
ICON plc Expands Share Buyback Program Amid Vaccine Study Delays and Tariff Uncertainty - TipRanks
Icon Plc [ICLR] Officer makes an insider purchase of 1,540 shares worth 0.29 million. - knoxdaily.com
Market Analysts see Icon Plc [ICLR] gaining to $150. Time to buy? - dbtnews.com
Icon (ICLR) Price Target Reduced by BofA Analyst | ICLR Stock Ne - GuruFocus
ICLR Faces Revenue Pressure Amid Elevated Cancellations - GuruFocus
Barclays Adjusts Price Target for Icon (ICLR) Amid Uncertain Out - GuruFocus
Barclays Adjusts Price Target for Icon (ICLR) Amid Uncertain Outlook | ICLR Stock News - GuruFocus
Icon PLC (ICLR) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Initiatives - Yahoo Finance
ICON Public Limited Company (NASDAQ:ICLR) Q1 2025 Earnings Call Transcript - MSN
ICON plc Reports Q1 2025 Financial Results - TipRanks
Icon Earnings: Macroeconomic Issues and Trial Delays Affect Our Near-Term View - Morningstar
Narrow-Moat Icon Faces Macroeconomic Issues and Trial Delays That Constrain Its Near-Term Outlook - Morningstar
The Future of Icon Plc: Analyzing ICLR - investchronicle.com
A look at ICLR’s current quarter earnings estimates - uspostnews.com
ICON's Q1 Earnings Surpass Estimates, Revenues Lag, Stock Down - Yahoo Finance
Icon Plc (ICLR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.52%
0.53%
자본화:
|
볼륨(24시간):